GridAI Technologies (GRDX) vs Lite Strategy (LITS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
GridAI Technologies (GRDX) has outperformed Lite Strategy (LITS) over the past year, gaining 20.0% versus a loss of 51.2%. Over five years, LITS leads with a -97.9% price change compared with -100.0% for GRDX. Lite Strategy is the larger company by market cap ($37.1 million vs $34.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GRDX | LITS |
|---|---|---|
| Share price | $4.80 | $1.22 |
| Market cap | $34.23M | $37.10M |
| 1-day change | +16.50% | -3.94% |
| YTD return | +3.00% | -7.58% |
| 1-year return | +20.00% | -51.20% |
| 5-year return | -99.99% | -97.90% |
| EPS (TTM) | $-5.65 | $-2.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.93 | $2.97 |
| 52-week low | $1.87 | $0.69 |
| Distance from 52-week high | -30.73% | -58.92% |
| Average volume | 104.68K | 462.76K |
| Shares outstanding | 7.13M | 30.41M |
| Employees | — | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GRDX has outperformed LITS by 71.2 percentage points over the past year.
About GridAI Technologies
GRDX stock →GridAI Technologies Corp., together with its subsidiaries, designs and develops an artificial intelligence (AI)-driven software and device platform that enables utilities, retailers, and large power users to manage load and distributed energy resources. It also develops Adrulipase, a recombinant lipase enzyme program for the treatment of exocrine pancreatic insufficiency.
Health Care · Biotechnology: Pharmaceutical Preparations
About Lite Strategy
LITS stock →Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
GRDX vs LITS FAQ
Which is bigger, GridAI Technologies or Lite Strategy?
Lite Strategy (LITS) is larger, with a market capitalization of $37.10M compared with $34.23M for GridAI Technologies (GRDX).
Which stock has performed better over the past year, GRDX or LITS?
GRDX returned +20.00% over the past 12 months, compared with -51.20% for LITS (price return, excluding dividends). Past performance does not predict future results.
Are GridAI Technologies and Lite Strategy in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.